Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
4
×
Tags
alnylam pharmaceuticals
boston blog main
clinical trials
life sciences
4
×
national blog main
rna interference
boston
boston top stories
drugs
aminolevulinic acid
fda
givosiran
new york blog main
new york top stories
onpattro
patisiran
accelerated approval
acute hepatic porphyria
acute hepatic porphyrias
akcea therapeutics
akin akinc
alirocumab
amgen
andrew fire
biotech
craig mello
evercore isi
evolocumab
heart attack
hereditary transthyretin amyloidosis
inclisiran
inotersen
john maraganore
joseph swartz
medicines co.
national top stories
new york
nobel prize
paul matteis
pcsk9 inhibitors
What
alnylam
4
×
drug
4
×
pharmaceuticals
4
×
medicine
rna
rnai
data
fda
interference
new
ok
second
seek
speedy
afternoon
ago
alnylam’s
approval
approved
based
cholesterol
cleared
evidence
far
gets
heart
history
indicated
landmark
lasting
long
looms
lowering
making
market
medco
medicines
nasdaq
nod
onpattro
Language
Current search:
alnylam
×
drug
×
photo
×
" life sciences "
×
pharmaceuticals
×
@xconomy.com
5 years ago
MedCo Touts New Data for Long-Lasting Heart Drug as Reckoning Looms
@xconomy.com
5 years ago
Alnylam Won’t Seek Quick FDA Nod For Second RNAi Drug
@xconomy.com
5 years ago
With New Data, Alnylam Could Seek Speedy OK For Second RNAi Drug
@xconomy.com
6 years ago
Alnylam Gets Landmark FDA OK For First-Ever RNAi Drug